Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2011-03-08
2011-03-08
Marx, Irene (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S200000, C530S356000, C514S002600
Reexamination Certificate
active
07901676
ABSTRACT:
A therapeutic composition and a method for rheumatoid arthritis is described. The composition comprises purified beta-glucuronidase at a concentration of between 200 and 10,000 Fishman units/ml and purified collagen at a concentration of between 0.5 and 2.5 mg/ml. The composition is administered by transdermal infusion or intradermal injection.
REFERENCES:
patent: 4510129 (1985-04-01), Knop et al.
patent: 5268463 (1993-12-01), Jefferson
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 2001/0056069 (2001-12-01), Klaus
patent: 2003/0118672 (2003-06-01), McPeak et al.
patent: 2006/0024334 (2006-02-01), Larche et al.
patent: 2008/0314333 (2008-12-01), Hurwitz
patent: 1 228 767 (2002-08-01), None
patent: 2205746 (1988-12-01), None
patent: 1218080 (1990-04-01), None
patent: WO 94/07520 (1994-04-01), None
Derwent patent abstract for JP 52076416A (1977), downloaded from WEST on Jul. 29, 2007 (1 page).
Terr, A. “Unproven and Controversial Forms of Immunotherapy” Clinical Allergy arid Immunol. (Dekker: NY, NY) (1999) 12: 479-488.
Terr, A. “Unproven and Controversial Forms of Immunotherapy” Clinical Allergy and Immunol. (Dekker: NY, NY) (2004) 18: 703-710.
The Merck Manual of Diagnosis and Therapy Berkow, Ed. (1987) (Merck Sharp & Dohme Research Laboratories: Rahway, NJ) p. 949-973.
Nemeth-Csoka et al. Frenius Zeitschrift fuer Analytisch Chemie (1984) 317(6): 690-2.
Jebens et al. J. Bone and Joint (1959) 418: 388-400, abstract.
Houli et al. Arquivos Interamericanos de Rheuatologia (1959) 2: 48-65, abstract.
Worth, J. (2001) www.talkeczema.com/webdocs/features/feature—epd.php; 8 pages; down-loaded on Feb. 5, 2010.
Jacox et al. J. Clin. Investigation (1955) 34: 263-7.
Annals of Allergy (1975), vol. 35(2), pp. 98-103, “Enzyme potentiated hyposensitization: V . . . ”, McEwen; see whole document.
Annals of Allergy (1975), vol. 34(5), pp. 290-295, “Enzyme potentiated hyposensitization: IV . . . ”, McEwen et al; see “Method”.
Cantani, et al., “Enzyme-Potentiated Desensitization in Children with Asthma and Mite Allergy: A Double-Blind Study”, Journal of Investigational Allergology and Clinical Immunology, 6(4):270-276, 1996.
Egger, et al., “Controlled Trial of Hyposensitization in Children with Food-Induced Hyperkinetic Syndrome”, Lancet 339(8802):1150-1153, 1992.
McEwen, et al., “Enzyme-potentiated Hyposensitization. 3. Control by Sugars and Diols of the Immunological Effect of Beta Glucuronidase in Mice and Patients with Hay Fever”, Annals of Allergy 31(11):543-550, 1993.
Menge, et al., “Monoclonal Autoantibodies from Patients with Autoimmune Diseases: Specificity, Affinity and Crossreactivity of Mabs Binding to Cytoskeletal and Nucleolar Epitopes, Cartilage Antigens and Mycobacterial heat-Shock Protein 60”, Immunobiology 205(1):1-16, 2002.
Wang, et al., “The influence of HLA-DR4 (0401) on the immune response to type 11 Collagen and the Development of Collagen Induced Arthritis in Mice”, Journal of Autoimmunity 18(2):95-103, 2002.
Matteson, E.L., Current Treatment Strategies for Rheumatoid Arthritis: Mayo Clinic Proceedings, Mayo Medical Ventures 75(1):69-74, 2000.
Vischer, T.L., “Oral Desensitization in the Treatment of Human Immune Diseases” Zeitschrift Fuer Rheumatologie, 54(3):155-157 1995.
Targoni, et al., “Prevention of Murine EAE by Oral Hydrolytic Enzyme Treatment” Journal of Autoimmunity, 12(3):191-198 1999.
Shrader, Jr., W.A. et al. “Enzyme Potentiated Desensitization (EPD)”White Paper for United States Senators and Representatives, The American EPD Study: 1993-2000, Sep. 2001 revised Oct. 15, 2001, pp. 1-14.
Astarita et al., “Effects of Enzyme-Potentiated Desensitisation in the Treatment of Pollinosis: A Double-Blind Placebo-Controlled Trial”,J. Invest. Allegol. Clin. lmmunol,. (1996) 6(4):248-55.
Fell et al., “A Single Dose Desensitization for Summer Hay Fever”,Eur. J. Clin. Pharmacol. (1990) 38:77-79.
Hershkoviz et al., “Keratinocytes-Associated Chemokines and Enzymatically Quiescent Heparanase Induce the Binding of Resting CD4+ T Cells.”J. Invest. Dermatol. (1996) 106(2):243-8.
Ho, K.J., “Activation of Human β-glucuronidase by Murine Monoclonal Antibodies and Bovine Serum Albumen”,Biochem. MI. Biol. Int. (1995) 36(6):1277-86.
Ippoliti et al., “Effect of Preseasonal Enzyme Potentiated Desensitisation (EPD) on Plasma-IL-6 and IL-10 of Grass Pollen-Sensitive Asthmatic Children”,Allerg Imrnunol, May 1997;29(5):120, 123-5.
Kondo et al., “Interleukin-10 Inhibits the Elicitation Phase of Allergic Contact Hypersensitivity”,J. Invest. Dermatol., (1994) 103:811-4.
Longo et al., “[Clinical Efficacy of a new Syposensitising Treatment, EPD (Enzyme Potentiated Desensitization) in the Therapy of Pollinosis]”,Riforma Med., (1992) 107:171-6.
McEwen et al., “Hyaluronidase in the Treatment of Allergy”,Brit Med. J., (1967) ii:507-508.
McEwan, L.M., “Effects of Sugars and Dials on Enzyme-Potentiated Hyposensitization”,J. Physiol, (1972) 230:65-66.
McEwen et al., “Enzyme Potentiated Hyposensitisation I: The Effect of Pre-Treatment with βglucuronidase, Hyaluronidase, and Antigen on Anaphylactic Sensitivity of Guinea-Pigs, Rats and Mice”,Int. Arch. Allergy(1972) 42:152-8.
McEwen, L.J., “Enzyme Potentiated Hyposensitization II: Effects of Glucose, Glucosamine, N-acetylamino Sugars and Gelatin on the Ability of βglucuronidase to Bock the Anamnestic Response to Antigen in Mice”,Annals of Allergy, (1973) 31:79-83.
McEwen, L.M., “A Double-Blind Controlled Trial of Enzyme Potentiated Hyposensitization for the Treatment of Ulcerative Colitis”,Clin. Ecol. (1987) 5(2):47-51.
Pipe, R.K, “Hydrolytic Enzymes Associated with the Granular Haemocytes of the Marine MusselMytuslis edulis”, Histochemical J. (1990) 22:595-603.
Edwards Angell Palmer & & Dodge LLP
Epidyme Limited
Hanley Susan
Hunter-Ensor, Esq. Melissa
Lauro, Esq. Peter C.
LandOfFree
Therapeutic composition for the treatment of rheumatoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic composition for the treatment of rheumatoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic composition for the treatment of rheumatoid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2750029